On June 18, 2023, the Second Anniversary of the Launch of Hansoh Pharma’s HengMu and Academic Conference with the theme of “Light of Life” was held in Shanghai. The event brought together distinguished top scholars and clinical experts in the field of viral hepatitis treatment to discuss the latest therapeutic advances for chronic hepatitis B and to provide a "Chinese solution" for the fight against hepatitis B worldwide.
Gather academic strength to address the challenges of treating chronic hepatitis B
Over 200 hepatology experts and clinicians gathered at the conference to review updates to the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition)” and discuss critical issues in the prevention and treatment of this disease. The conference emphasized the urgent need for collaboration among experts to achieve a “clinical cure” for chronic hepatitis B and help China eliminate viral hepatitis.
At the meeting, experts discussed the inclusion of HengMu (Tenofovir Amibufenamide Tablets, TMF) as a first-line treatment in the new version of the Guidelines. Professor Chen Enqiang, from West China Hospital of Sichuan University, presented recent real-world study data on TMF. The study evaluated the antiviral efficacy and safety of TMF compared to TAF when treating CHB patients, and its results were accepted by Frontiers and considered as an additional evidence of EBM after the inclusion of TMF in the Guidelines.
(Video of The Second Anniversary of the Launch of HengMu)
Chinese original research recognized internationally
HengMu was granted approval for marketing in June 2021 as the first original oral anti-hepatitis B innovative virus drug from China. Subsequently, it was included as a first-line treatment option in the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition)” in December 2022, offering enhanced antiviral treatment choices for clinicians. This novel nucleotide reverse transcriptase inhibitor features optimized structure, enabling greater cell membrane penetration for improved hepatocyte targeting. Furthermore, Heng Mu enhances drug plasma stability and reduces systemic TFV exposure, rendering long-term treatment safer.
In November 2022, 96-week data from a large phase III clinical study of Heng Mu was published in the Journal of Clinical and Translational Hepatology (JCTH), an internationally renowned academic journal on liver disease; in December 2022, Heng Mu was recommended for first-line treatment in the Chinese Expert Consensus on Antiviral Therapy for Hepatitis B Virus-Associated Hepatocellular Carcinoma (2023 Edition), reflecting the unanimous recognition of the efficacy and safety of Heng Mu by domestic experts in infectious hepatopathy and hepatobiliary surgery.
Benefited over 200,000 Chinese patients, contributing significantly to the "Healthy China" Initiative
Hepatitis B is a serious public health concern in China. However, in 2021, Heng Mu secured approval for marketing and inclusion in the National Reimbursement Drug List, marking a ground-breaking achievement for domestically produced drugs in this field. Over the last two years, HengMu has benefited more than 200,000 Chinese patients while crucially combating the growth of viral hepatitis and the associated fatalities of liver cancer and cirrhosis.
Hansoh Pharma is committed to shouldering its responsibilities by investing in scientific and technological research and development to advance prevention and drug treatment of chronic viral hepatitis. We aim to contribute to the elimination of hepatitis B and the realization of the Healthy China Strategy.
